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Abstract
Background: Chemokines are involved in many biological activities ranging from leukocyte
differentiation to neuronal morphogenesis. Despite numerous reports describing chemokine
function, little is known about the molecular changes induced by cytokines.
Methods: We have isolated and identified by differential display analysis 182 differentially
expressed cDNAs from CXCR3-transfected Jurkat T cells following treatment with CXCL12 or
CXCL10. These chemokine-modulated genes were further verified using quantitative RT-PCR and
Western blot analysis.
Results: One hundred and forty-six of the cDNAs were successfully cloned, sequenced, and
identified by BLAST. Following removal of redundant and non-informative clones, seventeen
mRNAs were found to be differentially expressed post treatment with either chemokine ligand
with several representing known genes with established functions. Twenty-one genes were
upregulated in these transfected Jurkat cells following both CXCL12 and CXCL10, four genes
displayed a discordant response and seven genes were downregulated upon treatment with either
chemokine. Identified genes include geminin (GEM), thioredoxin (TXN), DEAD/H box polypeptide
1 (DDX1), growth hormone inducible transmembrane protein (GHITM), and transcription
elongation regulator 1 (TCERG1). Subsequent analysis of several of these genes using semi-
quantitative PCR and western blot analysis confirmed their differential expression post ligand
treatment.
Conclusions: Together, these results provide insight into chemokine-induced gene activation and
identify potentially novel functions for known genes in chemokine biology.
Background
CXC and CC chemokines are small soluble proteins
expressed and secreted by a number of cell types during
the initial host response to injury, allergens, antigens, or
invading microorganisms [1]. These ligands selectively
attract leukocytes to inflammatory foci via facilitation of
cellular adhesion, transendothelial migration, chemotaxis
and cellular activation. Receptors for chemokines are
members of the large family of G-protein receptors that
signal via heterotrimeric guanine nucleotide-binding
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be subdivided into specific families based on their specif-
icity for C, CC, CXC, or CX3C chemokine ligands. Three
distinct types of receptor binding are currently recognized:
(1) chemokine receptors that bind only one chemokine
specific ligand; (2) chemokine receptors that bind more
than one chemokine often with different binding affini-
ties; and (3) promiscuous chemokine receptors that bind
to numerous chemokines [2].
The chemokine receptor CXCR4 binds to the CXC chem-
okine, CXCL12 and functions as a co-receptor for HIV-1
[3]. CXCR4 is broadly expressed by many cells within the
body including cells of the immune and the central nerv-
ous system [4-7]. This receptor mediates the migration of
resting leukocytes and hematopoietic progenitors in
response to its specific ligand [8,9]. CXCL12-induced
chemotaxis is inhibited by pertussis toxin, enhanced in
vitro by IL-3, and selectively inhibited by soluble ephrin-B
receptor. [10]. In addition, proinflammatory stimuli such
as lipopolysaccharide, tumor necrosis factor (TNF-α) or
interleukin-1 potentiates lymphocyte-and monocyte-, but
not neutrophil-mediated CXCL12 responses [11,12]. Fur-
thermore, CXCL12 is an extremely potent in vitro and in
vivo chemoattractant for mononuclear cells and lym-
phocytes [13]. CXCL12 is expressed in the cells forming
Hassall's corpuscles and plays a significant role in the
elimination of apoptotic thymocytes in normal and HIV-
1-infected thymic tissues [14]. In addition to the bone
marrow, quantitative PCR analysis has detected expres-
sion of CXCL12 in the lymph nodes, lung, and liver [15].
Autocrine and paracrine production of CXCL12 by
peripheral blood CD34+CD38+ cells also appears to trig-
ger their transition from G0 to G1 and, in conjunction with
thrombopoietin, enhances their survival through signal
transduction mediated by the PI3K/AKT proteins [16].
Together these data support a role for CXCL12 as a critical
factor for cellular growth and differentiation, cellular traf-
ficking, myelopoiesis, and organ vascularization [17,18].
In contrast to CXCL12, considerably less is known about
the chemokine CXCL10. CXCR3 (GPR9; CD183), the
receptor for CXCL10 also binds the CXC chemokines
CXCL9 and CXCL11 [19]. Recent studies of the CNS have
suggested that CXCR3 additionally binds CCL21 [20].
CXCL10 is secreted by a variety of cell types, including
monocytes, endothelial cells, fibroblasts, and astrocytes.
CXCL10 is also a chemoattractant for human monocytes,
natural killer and T cells (preferentially Th1 cells), and
appears to modulate adhesion molecule expression and
function [21-23]. CXCL10 is expressed in keratinocytes,
lymphocytes, monocytes, and endothelial cells during
Th1-type inflammatory diseases such as psoriasis and
atopic dermatitis, but only at very low basal levels in nor-
mal keratinocytes [24,25]. CXCL10 inhibits bone marrow
colony formation by CD34+ cells in the presence of stem
cell growth factor (SCGF), colony stimulating factor 2
(granulocyte-macrophage) (CSF2; GM-CSF), or a combi-
nation of SCGF and erythropoietin (EPO). Moreover,
CXCL10 has antitumor activity in vivo and is a potent
inhibitor of angiogenesis [26]. This antitumor activity
appears to be mediated by the ability of CXCL10 to recruit
lymphocytes, neutrophils, and monocytes into inflamma-
tory infiltrates. Moreover, CXCL10 has also been recently
shown to be a Ras target gene and is overexpressed by a
number of colorectal cancers [27]. Overall, CXCL10 is an
important chemokine for mediating delayed-type hyper-
sensitivity responses and a potent regulator of colony for-
mation, angiogenesis, adhesion and cell migration.
Alterations in gene expression are important determinants
of cellular physiology. As a consequence, the identifica-
tion, cloning and characterization of differentially
expressed genes can provide relevant and important
insights into a variety of biological processes. To investi-
gate and compare the similar and distinct genes induced
by the chemokines, CXCL12 and CXCL10, in normal
physiology, we utilized differential display analysis to
identify mRNAs in a Jurkat T cell line expressing endog-
enous CXCR4 and transfected with human CXCR3 gene.
We have identified and cloned several differentially
expressed genes displaying both elevated and diminished
expression in the context of specific chemokine receptor
ligation. The possible relevance of such differential
responses within normal immune responses and in nor-
mal T-cell physiology is discussed.
Table 1: Flow cytometric analysis of transfected Jurkat T cell lines
% Positive (MFI)
Cell Line CD3 CXCR4 CXCR3 CXCR2
Jurkat-Neo 98 (138) 99 (118) 2 (5) 4 (4)
Jurkat-CXCR3 98 (154) 99 (124) 99 (24) 5 (8)
Jurkat-Bcl2 96 (144) 96 (124) 5 (6) 7 (5)
CXCR3-, Bcl2-and Neo-transfected Jurkat T cells were stained using IgG FITC-labeled antibodies to CD3, CXCR4, CXCR3, and CXCR2 and 
analyzed for cell surface protein expression via flow cytometric analysis. The data are expressed as % positive (mean fluorescence intensity). It 
should be noted that the CXCR3-transfected Jurkat cells expressed low levels of CXCR3 on their cells surface suggesting a lower receptor density 
in comparison to CXCR4.Page 2 of 14
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Differential display
Total RNA was isolated using the Qiagen RNeasy® kit (Qia-
gen Inc., Valencia, CA) and treated with DNase I (Gen-
Hunter, Nashville, TN). Two micrograms of the total RNA
was derived from subclone of CXCR3-transfected Jurkat T
cells (generously donated by Dr. Thomas Hamilton,
Lerner Research Institute, Cleveland, OH) cultured for 24
h in the presence and absence of 1 µg/ml of bioactive
CXCL12 or CXCL10 (PeproTech). It should be noted that
the CXCR3-transfected Jurkat T cells were subcloned from
the original cultures. Subclones of the CXCR3-transfected
lines were initially generated at the initiation of these
studies so that homogenous CXCR3-bearing cells were
available. A single Jurkat subclone was selected and exam-
ined for coexpression of both CXCR3 and CXCR4 by flow
cytometry (Table 1). The isolated RNAs were subsequently
reverse-transcribed with 400 units of MMLV reverse tran-
scriptase (GenHunter) in three separate reactions each
containing 2 uM of a one-base-anchored H-T11M (i.e. H-
T11G, H-T11A and H-T11C) primer (RNAimage®, Gen-
Hunter) and 20 uM dNTP for 60 min at 37°C. After heat
inactivation of the reverse transcriptase at 75°C for 5 min,
2 µl of each reverse transcription reaction was added to 18
µl of a PCR master mix containing 2 uM of an H-T11-arbi-
trary primer, 1 U Taq polymerase (Qiagen), 2 uM dNTP,
and a-[33P]dATP. Each primer pair was denatured at 94°C
for 30 sec, annealed at 40°C for 2 minutes and extended
at 72°C for 30 sec for 40 cycles with a final extension for
10 minutes. [33P]-labeled PCR products were resolved on
a 6% denaturing polyacrylamide gel. The autoradiogram
was inspected on a light box and differentially expressed
bands marked by needle punches. The punched film was
carefully oriented on the dried gel and the marked bands
excised with a scalpel blade. Glycogen (10 mg/ml), 3 M
sodium acetate, and 85% EtOH were added and after
overnight storage at -80°C, the DNA was precipitated by
centrifugation. Each DNA was subsequently reamplified
using the same PCR primer set and conditions except that
the dNTP concentration was increased to 20 uM and no
isotope was added to the mixture. Reamplified PCR prod-
ucts were resolved on a 1.5% AmpliSize™ (BioRad, Rich-
mond, CA) agarose gel, stained with SYBR® Gold
(Molecular Probes, Eugene, OR) and extracted from the
gel using a QIAEX II kit (Qiagen). Successfully amplified
bands were cloned using the PCR-TRAP® cloning vector
system (GenHunter) and ligated into GH-competent cells.
Following transformation, only clones that contain an
insert are capable of growing on LB-Tet agarose plates. The
cloned insert was subsequently checked by colony-PCR
using primers flanking the PCR-TRAP® vector and the
insert sequenced to identify genes differentially expressed
between control and chemokine-treated CXCR3-trans-
fected Jurkat T cells.
Quantitative analysis of PCR fragments
One microgram of DNase I-treated total RNA from con-
trol, CXCL12-or CXCL10-treated CXCR3-transfected Jur-
kat T cells was reverse-transcribed with 200 units of
SuperScript II reverse transcriptase (Invitrogen, Carlsbad,
CA) in a 20 ul reaction for 50 min at 42°C followed by
heat-denaturation at 70°C for 15 minutes. Two microlit-
ers of the first strand reaction product were amplified in
six duplicate reactions using standard PCR conditions
(94°C for 1 minute, 63°C for 1 minute and, 72°C for 1
minute for 34 cycles) with sequence specific primers. Indi-
vidual tubes were removed after 24, 26, 28, 30, 32, and 34
cycles and the concentration of specific PCR product
determined using an Agilent 2100 BioAnalyzer and DNA
1000 LabChip (Agilent Technologies, Palo Alto, CA).
Each RT-PCR was performed twice for each RNA prepara-
tion. Two housekeeping control genes, GAPDH and ribos-
omal protein L32 (RPL32), were utilized as controls with
specific primers producing a 599 bp product for GAPDH
and a 233 bp product for RPL32.
Western blot analysis
Cells were lysed in modified RIPA cell lysis buffer (50 mM
Tris-HCl, pH 7.4, 1% NP-40, 1% sodium deoxycholate,
0.15 M NaCl, and 1 mM EDTA) with 1 mM phenylmeth-
ylsulfonylfluoride (PMSF), 1 mM sodium orthovanadate,
5 µg/ml leupeptin, 2 µg/ml aprotonin and one Complete
Protease Inhibitor Cocktail tablet (Roche Diagnostics
Corporation, Indianapolis, IN) per 50 ml of buffer. Whole
cell protein extract was used directly for Western blot anal-
ysis. Protein concentration was determined using Bio-Rad
protein assay kit (BioRad). Twenty micrograms of total
protein from each sample was separated on a 10% Tris-
glycine polyacrylamide gel and transferred onto a polyvi-
nylidene difluoride membrane (Invitrogen, San Diego,
CA). Membranes were blocked for 1 h at room tempera-
ture in PBS containing 5% non-fat dry milk and 0.1%
Tween-20. The membranes were then incubated over-
night at 4°C in primary antibody (anti-CA150, anti-
thioredoxin, anti-flotillin and anti-ferritin H chain, BD
Biosciences Transduction Laboratories, Lexington, KY and
Santa Cruz Biotechnologies, Inc, Santa Cruz, CA) diluted
1:1000 in PBS containing 5% non-fat dry milk and 0.1%
Tween-20. The membranes were washed in PBS with 0.1%
Tween-20 then incubated for one hour in secondary anti-
body (goat anti-mouse-HRP and rabbit anti-goat-HRP;
Santa Cruz Biotechnology, Inc., Santa Cruz, CA). The
blots were washed and the proteins detected using the
ECL Plus Western Blotting Kit (Amersham Biosciences UK
Limited, Buckinghamshire, UK) and X-MAT AR Film
(Eastman Kodak, Rochester, NY).
Cellular migrations and intracellular calcium mobilization
Jurkat T cell migration was examined using a fluorescence-
based Transwell chemotaxis assays as previouslyPage 3 of 14
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cells were labeled with 10 µg/ml Hoechst 33342 (Molec-
ular Probes) in cRPMI for 30 min at 37°C, and then
treated with chol-BCD as described above. The cells were
then resuspended in RPMI with 1% FBS to a concentra-
tion of 1 × 107/ml. RPMI (0.6 ml) containing 1% FBS with
or without 100 ng/ml SDF-1α was added to the bottom
wells of the 24-well plate. Transwell chambers with 5 µm
pore filters (Corning CoStar, Acton, MA) were then placed
into the wells. Cells (1–3 × 106 in 100 µl) were then added
to the chambers. After 2 h, the migrated cells in the bot-
tom wells were transferred to triplicate wells of a 96-well
plate in 150 µl volumes. Hoechst fluorescence was meas-
ured on a Fluoroskan Ascent FL fluorescence plate reader
(Thermo Labsystems, Franklin, MA) at λex = 355 nm, andλem = 460 nm. Results are expressed as migration index
calculated by subtracting the fluorescence intensity of
media alone and comparing the values to the fluorescence
intensity (relative number) of cells migrated into the bot-
tom chamber in media alone, which is normalized to a
value of 1. Fluorescence values were within the linear
range of a standard dilution curve.
CXCR3-transfected Jurkat T cells were loaded with the flu-
orescent indicator, Fura-2AM (Molecular Probes, Eugene,
OR), for 30 min, then washed and resuspended in PBS
containing calcium and magnesium at 106 cells/ml [61].
The ratio of free to bound intracellular calcium was deter-
mined by spectrofluorometry by monitoring absorption
at 340 nM versus 380 nM and emission at 510 nM. The
chemokines, CXCL12α and CXCL10 (Peprotech, Rocky
Hill, NJ) were utilized in these experiments at 1 µg/ml.
Results
CXCR3-transfected Jurkat T cells migrate and mobilize 
intracellular calcium in response to CXCL12 and CXCL10
The cells were found to be functionally responsive to both
CXCL12 and CXCL10. As shown in Fig. 1A, a subclone of
a CXCR3-transfected Jurkat T cell line, which was found
by flow cytometry to coexpress both CXCR3 and CXCR4
(Table 1), specifically migrated in response to CXCL12
and CXCL10 in a dose-dependent fashion. Optimal
migration for CXCL12 was noted at 0.5–1 µg/ml, while
optimal migration for CXCL10 was observed at 1 µg/ml.
In contrast, control neomycin phosphotransferase gene-
transfected Jurkat T cells only demonstrated responses to
CXCL12. Similarly, CXCR3-transfected Jurkat T cells dem-
onstrated a potent calcium mobilization in response to
CXCL12 (1 µg/ml) and a modest response to CXCL10 (1
µg/ml), while neo-Jurkat T cells failed to demonstrate any
CXCL10 response (Fig. 1B). The modest migration and
calcium mobilization observed in response to CXCL10
compared to CXCL12 in this cell line suggests either dis-
tinct signaling through CXCR3 or lower cell surface
CXCR3 density. Based on the flow cytometric data (Table
1), the mean fluorescence intensity for CXCR4 is approxi-
mately 5-fold greater than that for CXCR3 on this trans-
fected cell line. Similar levels of CXCR4 were expressed on
all of these cell lines including a neo control or Bcl2-trans-
fected cell Jurkat line. As expected, CXCR2 failed to dem-
onstrate any staining on these cell lines. While there may
be differences in CXCR4 and CXCR3 signaling in these
cells, differences in receptor density may influence the
CXCR3-transfected Jurkat T cells migrate and mobilize cal-cium in response to CXCL10 and CXCL12Figure 1
CXCR3-transfected Jurkat T cells migrate and mobi-
lize calcium in response to CXCL10 and CXCL12. 
CXCR3-transfected Jurkat T cells or neo-transfected Jurkat 
T cells (Panel A) were examined within Transwell chemo-
taxis chamber for their ability to migrate in response to vari-
ous concentrations of CXCL10 and CXCL12 as described in 
the Methods. The migration data are expressed as a migration 
index relative to the number of migrating cells in the absence 
of chemokine. Panel B shows the mobilization of intracellular 
calcium within CXCR3-transfected and control Jurkat T cells 
stimulated with CXCL10 or CXCL12 (1 µg/ml). The data 
points were collected every 0.48 s and are presented as the 
relative ratio of fluorescence excited at 340 and 380 nm. 
Arrows indicate when the chemokine was added to the 
chambers. The insert within Panel B is a close-up view of the 
CXCL10 response within CXCR3-transfected Jurkat T cells. 
We have never observed any calcium mobilization or chemo-
tactic activity by non-transfected or neo-transfected Jurkat T 
cells in response to CXCL10 (data not shown).Page 4 of 14
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below and thus cannot be ruled out.
Differential display of mRNA expression in CXCL12-and 
CXCL10-treated T cells
In an effort to identify genes, which may be upregulated
or downregulated by CXCL12 or CXCL10, we examined
Jurkat T cells that that expressed endogenous CXCR4 and
that had been transfected with CXCR3 using DDRT-PCR
analysis (Figure 2, Table 1). Jurkat T cells were stimulated
with either CXCL12 or CXCL10 at a concentration of 1 µg/
ml for 24 hr. The dose of 1 µg/ml was selected as this con-
centration yielded optimal migration for both CXCL12
and CXCL10 in the CXCR3-transfected T cells. Total RNA
prepared from normal and chemokine-stimulated Jurkat
cells were reverse transcribed into cDNA. The resultant
cDNAs were amplified with 45 combinations of the arbi-
trary and oligo(dT) anchored primers. Seventeen cDNA
bands were found to be differentially expressed in
CXCR3-transfected Jurkat T cells. Fig. 3 shows the repre-
sentative differential display results obtained with six sep-
arate primer combinations. Two cDNA fragments,
designated as C31.3 (ribosomal protein S25) and A6.7
(thioredoxin) were identified to be differentially
expressed by chemokine treated but not in untreated Jur-
kat cells (Fig. 3A and 3B). The cDNA fragments were
excised from the gel, reamplified, subcloned and
sequenced.
Direct sequencing of DDRT-PCR products
To characterize the sequence identity of DDRT-PCR prod-
ucts, the excised and re-amplified bands were cloned into
the PCR-TRAP vector and transformed into GH-compe-
tent E. coli. Several colonies were selected to be cultured,
plasmids were purified, and the inserts wee subsequently
screened by colony-PCR using primers flanking the site of
the PCR-TRAP vector. The plasmids containing an insert
were sequenced. We successfully sequenced a total of 146
cDNAs. Seventeen mRNAs were differentially expressed
post treatment with either CXCL12 or CXCL10, each rep-
resenting known genes with established functions. Five
additional RNAs were also identified defining known
genes with unknown functions and nine identified hypo-
thetical or predicted genes of unknown function (Table
2). Twenty-one genes were upregulated in CXCR3-trans-
fected Jurkat cells following both CXCL12 and CXCL10,
four genes displayed a discordant response and seven
genes were down regulated by both chemokines (Fig 3).
Sequence analysis indicated that the 401 bp A4.7 cDNA is
highly homologous to the gene LOC51053 that is also
known as geminin, a cell cycle regulator. The 157 bp A6.7
cDNA fragment is 94% identical to the 501 bp human
thioredoxin (TXN) gene. The sequence of the band A11.1
was homologous to the transcription elongation regulator
1 gene (TCERG1) also known as CA150. The 329 bp C7.3
cDNA fragment is 87% identical to the published human
gene encoding the growth hormone inducible transmem-
brane protein (GHITM). The sequence of the band C10.4
was homologous to the interferon-induced transmem-
brane protein 2 (IFITM2) gene, a member of the 1–8 gene
family whose members are strongly induced by both type
I (IFNα, IFNβ) and type II (IFNγ interferons). The 102 bp
G1.1 cDNA fragment is 97% identical to the human gene
encoding flotillin 1 (FLOT1) that is thought to play a role
in vesicular trafficking and signal transduction. Sequence
analysis indicated that the 444 bp G9.2 cDNA, as well as
several other bands, were highly homologous (>95%) to
the gene encoding the iron-storage protein ferritin heavy
polypeptide 1 (FTH1). The sequences of the other cDNAs
included in Table 2 showed significant homology to pub-
lished sequences in Genebank. However, it should be
noted that in a number of cases, the nucleotide sequence
of the cDNA matched named genes about which little is
known or matched, in some cases for over 500 bp, the
sequence of hypothetical or predicted genes. Several ribos-
omal proteins including L7, S12 and S25 and ferritin
Flow chart of the RT-PCR-based differential display procedureigure 2
Flow chart of the RT-PCR-based differential display 
procedure. A detailed description of each step is found in 
the Methods.Page 5 of 14
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DDRT analysis. In Figure 4, these changes in gene expres-
sion as assessed by DDRT are more clearly displayed post
cluster analysis using an arbitrary densitometric scale of
0–4 for all named genes found by DDRT-PCR. Red indi-
cates upregulation and green down-regulation in response
to chemokine treatment.
Identification of differentially expressed RNA transcripts 
associated with CXCL12 or CXCL10 treatment
As a large fraction of DDRT-PCR products have been
shown to yield weak or barely detectable signals in the
Northern blot analysis, we sought to confirm the identity
and differential expression of these bands via RT-PCR
analysis. We focused our attention on a subgroup of the
seventeen DDRT-PCR products representing known genes
with established functions. Gene specific primers were
designed to produce unique amplimers between approxi-
mately 150 and 500 base pairs in size.
RT-PCR analysis was performed on the Agilent BioAna-
lyzer 2100 System. The advantage of using this system to
examine competitive PCR products lies in the accurate
absolute and relative quantitation of each amplified prod-
uct. Small differences in the amount of amplimer product,
which cannot be detected using slab gel analysis, are more
easily analyzed on this equipment permitting RT-PCR to
be used to measure changes in gene expression. RNA from
CXCR3 receptor-transfected T cells, both before and post
treatment with CXCL12 or CXCL10 was reverse
transcribed in bulk and aliquots RT product amplified by
PCR using specific sets of primers. Initially, a 599 bp
GAPDH amplimer was utilized as a housekeeping gene.
However, it was noted that GAPDH significantly up-regu-
lated post treatment of the cells with either CXCL12 or
CXCL10. To address this issue, a 233 bp ribosomal pro-
tein L32 amplimer was utilized as a housekeeping gene for
the subsequent comparison of gene expression levels. In
Figures 5 (CXCL12) and 6 (CXCL10), each of the seven
genes (FLOT1, GEM, GHITM, FTH1, IFITM2, TXN and
TCERG1) examined were found to be either up-regulated
or down-regulated as predicted by the differential display
autoradiogram bands in Fig. 3. However, there was little,
if any, relationship between the intensity of the DD band
and the quantity of PCR product subsequently detected.
These quantitative RT-PCR data confirm our DDRT data
and support CXCL12-and CXCL10-mediated gene regula-
tion in the Jurkat line. It should be noted that given that
we are utilizing CXCR3-transfected Jurkat T cells in these
studies, it is quite possible that differences in CXCR3 and
CXCR4 receptor density and signal molecule association
may influence the genes induced in response to these
chemokines. Moreover, as high doses of chemokine were
utilized in the stimulation cultures (1 µg/ml), these supra-
physiologic concentrations may also differentially influ-
ence the observed differences in gene expression.
Additional studies were performed using primary human
T cells derived from several different donors to verify the
differential CXCL12-and CXCL10-induced gene expres-
sion observed in Jurkat T cells. However, despite the clear
differences in gene expression in Jurkat T cells after
chemokine stimulation for 24 hr in culture, primary rest-
ing and anti-CD3/CD28 mAb-activated human T cells
demonstrated variable and non-reproducible expression
of the geminin, thioredoxin, DDX1, GHITM and TCERG1
gene products (data not shown). This variability may have
more to do with the activation state of the primary T cells
being utilized and the chemokine receptor expression and
density on primary T cells versus the CXCR3-transfected
Differential display autoradiographyFigu  3
Differential display autoradiography. Panel A and B 
show examples of DDRT-PCR autoradiographs. Chemokine 
treatments are indicated above and the primer combinations 
below each cell lane. Panel C shows densitometric measure-
ments of the relative gene expression of individual bands 
after treatment of the transfected Jurkat T cells with 1 µg/ml 
of CXCL12 or CXCL10 for 24 hrs.Page 6 of 14
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CXCL12-induced gene expression in primary human T
cells at various stages of activation are the focus of current
studies. Moreover, studies using CXCL10 on primary
human T cells are quite difficult as the expression of
CXCR3 on resting human T cells is quite low to non-exist-
ent (>5% on CD3+ T cells with MFI between 5–12) and
may be selectively expressed on certain cell subsets.
CXCR3 studies in normal human T cells would require an
activation of T cells using IL-2 or Th1 polarizing stimuli
and thus may not be a valid comparison with the Jurkat T
cells utilized in these studies.
Protein expression in Jurkat T cells post CXCL12 treatment
To further confirm the expression of several of these
genes, Western blot analysis was subsequently performed
on total cell lysates of CXCL12-or gp120 IIIB-treated Jur-
kat T cells. The results shown in Fig. 7A demonstrate that,
similar to its gene expression, TCERG1/CA150 levels
increased in Jurkat T cells cultured with CXCL12 or the
HIV glycoprotein, gp120 IIIB, over a 24 hr time period.
This expression was found to be CXCR4-dependent as
neutralizing antibody to CXCR4 (but not control mouse
IgG) inhibited the CA150 increase in response to CXCL12
and gp120 IIIB. This CA150 increase was inhibited by the
addition of pertussis toxin, a Gα1 inhibitor. Given that
gp120 IIIB binds to both the CD4 and CXCR4 molecules
on the surface of human T cells, the similar results
between CXCL12 and gp120 IIIB treatment suggests an
active signaling role for gp120 IIIB through CXCR4. Figure
7B demonstrate that TCERG1 (CA150) and thioredoxin
were both increased post CXCL12 treatment. In addition,
although not identified in our DD studies, the signaling
protein, interferon regulatory factor-1 (IRF-1), was also
examined on our gels and increased significantly within
Jurkat T cells post CXCL12 treatment. Similar to its gene
expression, the gene product, flotillin-1, was found to be
decreased post CXCL12 treatment in several experiments;
however, these results were found to be highly donor var-
iable (data not shown). We believe that this variability
Table 2: Differentially expressed genes post chemokine treatment.
BAND Bp GENE LOCUSLINK GENEACC NAME
C10.5 AD24 64318 NM_022451 AD24 protein
A09.4 BM-002 51569 NM_016617 BM-002 hypothetical protein
A09.2 DDX1 1653 NM_004939 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 1
C27.3 DDX30 22907 NM_014966 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 30
G04.3 DFKZp564M113 none AL049282 Homo sapiens, clone MGC:5564, mRNA
A10.3 DFKZp566D193 25847 AL050051 DFKZp566D193 protein
A25.1 EIF4B 1975 NM_001417 eukaryotic translation initiation factor 4B
A28.3 EPB41L2 2037 NM_001431 erythrocyte membrane protein band 4.1-like 2
C10.1 FLJ12876 64767 NM_022754 hypothetical protein FLJ12876
G01.1 101 FLOT1 10211 NM_005803 flotillin 1
G09.2 444 FTH1 2495 NM_002032 ferritin, heavy polypeptide 2
C07.3 329 GHITM 27069 NM_014394 growth hormone inducible transmembrane protein
C10.4 IFITM2 10581 NM_006435 interferon induced transmembrane protein 2 (1–8 D)
A01.2 INVS 27130 NM_014425 inversin
C03.3 KIAA0478 9923 NM_014870 KIAA0478 gene product
G04.6 KIAA0648 23244 AB014548 KIAA0648 gene product
G01.4 KIAA1600 57700 AB046820 KIAA1600 protein
A04.7 401 LOC51053 51053 NM_015895 geminin
C35.1 LOC51633 51633 NM_016023 CGI-77 protein
G35.1 MAP3K10 4294 NM_002446 mitogen-activated protein kinase kinase kinase 10
A27.14 MGC10744 84314 NM_032354 hypothetical protein MGC10744
C15.3 MGC4809 91860 AF308287 serologically defined breast cancer antigen NY-BR-20
A25.3 NCBP1 4686 NM_002486 nuclear cap binding protein subunit 1,80 kD
A27.12 NCBP2 22916 NM_007362 nuclear cap binding protein subunit 2, 20 kD
G11.1 RPL7 6129 NM_000971 ribosomal protein L7
G30.2 RPS12 6206 NM_001016 ribosomal protein S12
C31.3 RPS25 6230 NM_001028 ribosomal protein S25
A11.1 TCERG1 10915 NM_006706 transcription elongation regulator 1 (CA150)
A06.7 157 TXN 7295 NM_003329 thioredoxin
C15.5 VIT1 55519 NM_018693 vitiligo-associated protein VIT-1
G03.6 WBP11 51729 NM_016312 WW domain binding protein 11Page 7 of 14
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BMC Immunology 2004, 5:17 http://www.biomedcentral.com/1471-2172/5/17Comparison of the relative gene expression by CXCL12-versus CXCL10-treated T cellsFigure 4
Comparison of the relative gene expression by CXCL12-versus CXCL10-treated T cells. Changes in gene expres-
sion were displayed using computer programs (Cluster, Tree-View-Eisen) using an arbitrary densitometric scale of 0–4 for all 
named genes found by DDRT-PCR. Red indicates upregulation, green down-regulation, and black-to-gray means no change. 
The columns are labeled as C (Vehicle control), S (CXCL12), and I (CXCL10).Page 8 of 14
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BMC Immunology 2004, 5:17 http://www.biomedcentral.com/1471-2172/5/17was most likely due the use of total cell lysates instead of
membrane preparations. In addition, despite examining
numerous lysates preparations and blots, we were unable
to detect ferritin heavy chain expression by Western blot
in any of these studies.
Discussion
Studies on the alteration of gene expression following
chemokine-receptor ligation and the identification of
genes that are differentially expressed can provide relevant
and important insight into a variety of biological proc-
esses and disease etiologies. To date, numerous
approaches, model systems, and techniques have been
Quantitative RT-PCR measurement and verification of CXCL12- nduced gene expressionFigure 5
Quantitative RT-PCR measurement and verification 
of CXCL12-induced gene expression. A detailed 
description of the procedure employed is found in the Meth-
ods. Each transcript was normalized to the expression of 
RPL32 in the same PCR reaction.
Quantitative RT-PCR measurement and verification of CXCL10- nduced gene expressionFigure 6
Quantitative RT-PCR measurement and verification 
of CXCL10-induced gene expression. A detailed 
description of the procedure employed is found in the Meth-
ods. Each transcript was normalized to the expression of 
RPL32 in the same PCR reaction.
CA150/TCERG1, thioredoxin and IRF-1 protein expression by Jurkat T cells post CXCL12α treatmentFig e 7
CA150/TCERG1, thioredoxin and IRF-1 protein 
expression by Jurkat T cells post CXCL12α treat-
ment. Jurkat cells were treated for 24 hrs with either 
CXCL12 (A, B) or gp120 IIIB (A) at 1 µg/ml in the presence 
or absence of control mouse IgG, mouse anti-human CXCR4 
mAb, or pertussis toxin (PTx; 200 ng/ml) at 37°C. After incu-
bation, the cell pellets were isolated, counted, washed, and 
subsequently lysed with the detergent. Protein determina-
tions were then performed. Samples were loaded at 20 µg 
per lane on a 10% polyacrylamide gel. After electrophoresis, 
the gels were transferred using a transfer apparatus to an 
immobilon membrane and stained for CA150/TCERG1 (A, 
B), thioredoxin (B) or IRF-1 (B) expression via Western blot 
analysis (shown in panel B for each of these proteins versus 
control). The results are expressed as fold change versus 
control expression (post background subtraction).Page 9 of 14
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[28-33]. In the present study, we used the PCR differential
display method to screen genes and compare the changes
that occur following CXCL12/CXCR4 and CXCL10/
CXCR3 ligation. Both the CXCR3 and CXCR4 chemokine
receptors are broadly expressed in many tissues and liga-
tion to their specific chemokines is known to result in
downstream signaling through several different pathways
such as Ras, and PI3 kinase. PI3 kinase and JAK/STAT sig-
naling pathways activated by CXCL12/CXCR4 ligation
play roles in lymphocyte chemotaxis in response to these
signals [34-37]. Although less well characterized, the
interaction of CXCR3 with its ligands, in this case
CXCL10, results in increased chemotaxis and activation of
the Ras/ERK cascade as well as stimulation of Src
phosphorylation and kinase activity and increased activity
of phosphatidylinositol 3-kinase and its downstream
pathway Akt [38]. Despite knowledge of the activation of
multiple cytokine-induced signaling pathways, an
understanding of the transcriptional mechanisms
whereby CXCR3 and CXCR4 ligation regulates and medi-
ates cellular change remains largely unknown.
In the present study, we have identified 31 cellular genes
that were either up-or down-regulated in CXCR3-trans-
fected Jurkat T cells following treatment with either
CXCL12α or CXCL10. Suzuki and colleagues [30] have
recently examined gene expression in Jurkat T cells treated
with 380 ng/ml of CXCL12 (a dose that demonstrated
optimal Jurkat migration in their hands) for various time
periods up to 12 hours in the presence or absence of
serum using cDNA microarray gene analysis. The arrays
utilized were 2140 cDNA microarray with 1847 unique
genes http://nciarray.nci.nih.gov/cgi-bin/gipo. Many of
the genes identified in this study are associated with
detoxification, DNA repair, apoptosis, migration, T cell
receptor signaling and interferon signaling. While many
of the chemokine-induced genes observed in our study are
not found on the arrays used by Suzuki et al. [30], we did
identify several genes and proteins with similar functional
associations as this group, namely interferon-induced
transmembrane protein 2 and interferon regulatory fac-
tor-1 (interferon-associated genes), thioredoxin and ferri-
tin (detoxification/redox), growth hormone inducible
transmembrane protein (apoptosis), flotillin-1 (cell
signaling and migration) and geminin (cell signaling/
division). It should be noted that we do believe there are
differences in the systems utilized by our groups as we
failed to confirm using real time RT-PCR and flow cytom-
etry several of the genes identified by Suzuki et al. Differ-
ences in the cell lines (bulk line vs. subclone vs.
transfected), culture conditions, serum status, dose of
chemokine utilized (380 ng/ml vs. 1 µg/ml) and receptor
density may account for such disparity. Regardless of
these differences, the relationship between the genes iden-
tified in our current study and those within the Suzuki
study and their role in chemokine biology and function
remains to be determined.
Although not previously linked to chemokine receptor-
ligand signaling, expression of several of these genes such
as interferon-induced transmembrane protein 2 (IFITM2)
and growth hormone inducible transmembrane protein
(GHITM) are recognized to be a part of the interferon sig-
naling system that includes Janus kinases and their down-
stream target STAT proteins [39,40]. IFITM2 is a member
of the large 1–8 gene family whose members are strongly
induced by both type I (IFNα, IFNβ) and type II (IFNγ)
interferons [41,42]. However, additional information
regarding the molecular function of this protein remains
unknown. Likewise, information about the molecular
function of GHITM is also quite sparse. GHITM displays
some similarity to the testis-encoded transcript (TEGT).
While the function of TEGT is also unknown, its amino
acid sequence predicts a 26.5 kDa integral membrane pro-
tein with seven potential transmembrane domains
suggesting a possible receptor function [43]. Interestingly,
TEGT is 100% homologous to BAX-inhibitor 1 (BI1)
[44,45]. Studies of cells overexpressing BI1 have shown its
role as a regulator of cell death pathways controlled by
BCL2 and BAX [44]. GHITM has also been referred to by
several other names including DERP2, My021, PTD010
and HSPC282. DERP2 is a novel protein originating in
human hair papilla cells that has an effect on regulating
the growth of hair. The logic behind relating these
seemingly inane associations is further supported by
knowledge that hair follicle development requires Sonic
hedgehog expression [46] that is essential for CXCL12 sig-
naling in the CNS [47,48].
The transcriptional cofactor, CA150, whose gene is now
designated transcription elongation regulator 1
(TCERG1) is capable of repressing transcription from
many viral and cellular promoters whose initiation is
dependent upon the presence of a TATA box [49]. CA150
represses RNA polymerase II (RNAPII) transcription by
inhibiting the elongation of transcripts. CA150 is a tran-
scriptional co-activator of HIV-1 Tat and therefore is likely
to regulate many cellular genes involved with cell signal-
ing, proliferation and differentiation [50]. A portion of
the CA150 molecule contains six FF domains and this
region appears to directly bind to the phosphorylated car-
boxyl-terminal domain of the largest subunit of RNAPII.
WW1 and WW2 functional domains are also found in
CA150 near the FF domains and appear to fine-tune the
repression of transcription through their association with
the ubiquitous splicing-transcription factor SF1. At
present, CA150 is believed to bind to the phosphorylated
C-terminal repeat domain of RNA polymerase II of the
elongating RNAPII with SF1 targeting the nascent tran-Page 10 of 14
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regulated in all-trans retinoic acid (ATRA)-induced apop-
tosis of H9 and SR-786 T cell lymphoma cell lines [52]
and to be significantly increased in striatal and cortical
brain tissue from individuals with the neurodegenerative
disorder Huntington's disease (HD) [53]. Interestingly, a
small subset of HD patients with early onset of symptoms
have a mutation in the region of the HD gene that
increases its binding to CA150 leading to the suggestion
that CA150 may interfere with the transcription of genes
essential for neuronal survival. Despite these findings, the
role of CA150 in T cell activation and survival is currently
unknown.
Geminin (LOC51053) is a 25-kDa protein that inhibits
DNA replication and is degraded during the mitotic phase
of the cell cycle [54]. This protein has generated consider-
able interest due to its critical role in replication licensing
[55,56]. In order to successfully replicate, eukaryotic cells
must assure that their chromosomes are duplicated only
once in each cell cycle. A process called "licensing" assures
that chromatin can only undergo another round of repli-
cation after it has passed through mitosis. Geminin
inhibits DNA replication by accumulating during met-
aphase, binding to and inactivating CDT1 and then
undergoing degradation during the metaphase to ana-
phase transition [54,57]. It is hypothesized that geminin
may have evolved to couple S-phase regulation to growth
and development signals [55]. As geminin is a powerful
negative regulator of the cell cycle, it also may function as
a tumor suppressor protein.
Flotillin-1 (FLOT1), also known as Reggie-2, encodes a
caveolae-associated, integral membrane protein [58].
Caveolae are small indentations on the plasma mem-
brane that are involved in vesicular trafficking and signal
transduction. Purified caveolin-rich membranes are
enriched for a variety of lipid-modified signaling mole-
cules such as G proteins, Src family kinases, Ras and nitric
oxide synthetase [59] and also are populated with mem-
bers of several families of integral membrane proteins
[60]. Recently, flotillin 1 and flotillin 2 have been recog-
nized to comprise a second family of integral membrane
caveolin proteins. The function of these flotillins has not
been determined but their expression levels are independ-
ent of the other caveolin family members. In at least some
cell types, caveolins and flotillins are capable of forming
hetero-oligomeric complexes and are believed to play a
role in receptor signaling [60].
Movement of CCR5 and CXCR4 molecules into lipid rafts
is important in the maintenance of receptor conformation
and through this mechanism rafts modulate the binding
and function of receptors [61,62]. Flotillin 1 and 2 along
with stomatin are the major integral protein components
of erythrocyte lipid rafts [63]. Although flotillins are
major components of caveolae, these proteins may also be
components of lipid rafts in other differentiated cell types
such as adipocytes, endothelial cells, fibroblasts and
immune cells.
Thioredoxin (TXN) is a 12-kDa oxidoreductase enzyme
containing a dithiol-disulfide active site. It possesses a
variety of biological functions including the ability to
modulate the DNA binding activity of the ligand-activated
transcription factor aryl hydrocarbon receptor (AHR) as
well as the activity of several other transcription factors
including general transcription factor IIIC, NF-κB, and AP-
1 [64,65]. Reactive oxygen species generated through
cellular metabolism can function as cellular second mes-
sengers through the regulation of numerous signal
transduction pathways. Thioredoxin protects cells against
TNF-induced cytotoxicity, general oxidative stress and is
able to scavenge free radicals [66]. As increasing evidence
accumulates that oxidative stress plays a crucial role in
many age-associated diseases and various neurodegenera-
tive disorders, the importance of regulating and maintain-
ing cellular redox status by intracellular redox-regulating
molecules such as thioredoxin becomes important to
maintain tissue homeostasis [67-69].
Ferritin is a highly conserved iron-binding protein that in
its cytosolic form is composed of 2 subunits, ferritin H
and ferritin L, each encoded by a distinct gene. Depending
on many factors including tissue type, redox status, and
the inflammatory state of a given cell or tissue, the ratio of
H to L subunits varies greatly [70]. Several proinflamma-
tory cytokines including TNFa, IL-1a (but not IL-1β, IFNg
and IL-6) has been shown to transcriptionally induce fer-
ritin heavy chain (FTH1) expression [71,72]. TNFa regula-
tion of FTH1 is through its binding to the p50 and p65
subunits of NFκB [73]. In addition, expression of FTH1
appears to be regulated by insulin, IGF-1 and thyroid hor-
mone [74,75]. Cytokines also regulate the post-transcrip-
tional modification of ferritin possibly through their
ability to induce iNOS [74,75]. As noted by Torti & Torti
[70], the pathways that link ferritin gene expression with
cell stress and altered growth regulation are just beginning
to be explored and based on present knowledge are very
complex and multifaceted.
Conclusions
In the current report, we do not reveal a specific physio-
logical role for the gene expression changes that have been
observed by DDRT-PCR post CXCL12 or CXCL10
signaling. As noted above, many of the more fully charac-
terized genes have multiple interactions utilizing a
number of distinct signaling pathways (e.g., JAK/STAT,
AP-1) that are frequently utilized by other cytokine family
members. A more detailed understanding of the variousPage 11 of 14
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their cell surface receptors or during the chemotactic proc-
ess should provide some insight into the process of cell
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